+9.7%
Revenue — year over year
$2.5B vs $2.3B a year ago · quarter ended Jun 30, 2026 · from 10-Q XBRL filings.
SEC filings and exhibits only
Earnings filing (8-K) · Latest 10-Q filings
Last updated: Oct 29, 2026 at 8:30 PM UTC
Earnings filing (8-K) · Latest 10-Q filings
Last updated: Oct 29, 2026 at 8:30 PM UTC
ACCOUNTING RISK · CLEAR
No auditor changes, restatements, late filings, or listing notices in the last 12 months.
from SEC filings · 2026-10-09
Thesis change
Weakened
Legacy analysis
Detailed dimension scores were not computed for pre-v1 analyses. Full six-dimension scoring resumes with filings processed by the current pipeline.
- Legacy analysis: scored by the pre-v1 pipeline; deep evidence has not been re-verified.
- 6 thesis dimension(s) lack comparable evidence
Reported facts
GAAP facts are reported by the company. Comparable figures are EarnIQ arithmetic using only quantified adjustments disclosed in the linked SEC exhibit.
Reported EPS and revenue have not yet been extracted from the filing.
Earnings quality
From 10-Q / 10-K XBRL filings. Sloan (1996) accruals: high accruals relative to assets have historically preceded earnings disappointments. Descriptive research, not a prediction.
Good — cash is doing the heavy lifting
Earnings look cash-backed — accruals are -3.3% of assets, in the strongest quintile of large caps.
CY2021Q2Accruals / assets (TTM)CY2025Q4
Depreciation is disclosed annually by most filers, so quarterly values blend actuals with estimates — flagged on every reading. Method: TTM Sloan accruals ÷ average assets, scored 1–5 by quintile.
1. Three decisive changes
Largest quantified changes versus the company's own history.
-1.2%
Gross profit — year over year
$560.0M vs $567.0M a year ago · quarter ended Jun 30, 2026 · from 10-Q XBRL filings.
+0.5%
Net income — year over year
$183.0M vs $182.0M a year ago · quarter ended Jun 30, 2026 · from 10-Q XBRL filings.
2. Was it already expected?
Consensus classifications require timestamped pre-report snapshots and eight-quarter surprise history.
| Item | Actual | Expected | Gap | Class |
|---|---|---|---|---|
| Consensus comparison coming soon. | ||||
3. Management consistency
Only attributable, measurable and dated commitments are counted. Delivery record: 2 being tracked.
| Promise | Target | Outcome | Status | Evidence |
|---|---|---|---|---|
| We remain on track to reduce costs by $125 million to $150 million, net of inflation in 2026.other · made 2026-10-29 | $125 million to $150 million2026 | — | Pending | 8-K 0000915389-26-0001 |
| We remain on track to implement approximately $500 million of selling price increases in 2026other · made 2026-10-29 | $500 million2026 | — | Pending | 8-K 0000915389-26-0001 |
4. What matters next
One deciding measurable condition plus up to two supporting checkpoints.
The deciding condition
EPS for the guided period lands within $6–$6.2
StrengthensReported EPS above $6.2
InvalidatesReported EPS below $6
Projected full-year 2026 adjusted earnings per share between $6.00 and $6.20 and operating cash flow of approximately $850 million.
5. Risks that changed
New or materially worsened items only; unchanged boilerplate is omitted.
No new or materially worsened risk has been source-verified.
From 10-K filings · EDGAR
8
new risk disclosures added
2
old ones removed
FY2025 10-K vs prior year, boilerplate filtered out — these are idiosyncratic changes, and tone is slightly more negative.
New risk disclosure #1
“business, the divestiture could reduce Eastman's revenue and, potentially, margins and increase its costs and liabilities in the form of transition costs and retained liabilities from the operations divested, including e…”
New risk disclosure #2
“Risks Related to the Company's Business and Strategy The Company's business is subject to operating risks common to chemical and specialty materials manufacturing businesses, any of which could disrupt manufacturing oper…”
New risk disclosure #3
“penalties, fines, civil, or criminal sanctions and remediation costs. Eastman has incurred, and will continue to incur, significant costs and capital expenditures to comply with these laws and regulations, which may adve…”
6. Evidence drawer
Source location, short anchor and visible arithmetic for every verified claim.
DC1 10-Q / 10-K XBRL filings (US-GAAP, via EDGAR)
Revenue · quarter ended 2026-06-30Revenue: +9.7% year over year
(2,513,000,000 − 2,290,000,000) ÷ 2,290,000,000 = +9.7% YoYDC2 10-Q / 10-K XBRL filings (US-GAAP, via EDGAR)
Gross profit · quarter ended 2026-06-30Gross profit: -1.2% year over year
(560,000,000 − 567,000,000) ÷ 567,000,000 = -1.2% YoYDC3 10-Q / 10-K XBRL filings (US-GAAP, via EDGAR)
Net income · quarter ended 2026-06-30Net income: +0.5% year over year
(183,000,000 − 182,000,000) ÷ 182,000,000 = +0.5% YoYWN1 8-K Exhibit 99.1 (earnings release, via EDGAR)
Guidance disclosed for Q3 FY2026EPS for the guided period lands within $6–$6.2
Strengthens: Reported EPS above $6.2 · Invalidates: Reported EPS below $6